Naproxeno Labesfal (Naproxen)

Naproxen blocks the activity of cyclo‑oxygenase enzymes COX‑1 and COX‑2, preventing the conversion of arachidonic acid into prostaglandins. Lower prostaglandin levels lead to decreased inflammation, reduced pain signalling, and a lowered fever response, providing symptomatic relief in the conditions for which it is prescribed.

The specific dose and dosing schedule of Naproxeno Labesfal are determined by the prescribing healthcare professional based on the patient’s condition, age, weight, and overall health. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Safety of naproxen during pregnancy and lactation depends on the trimester and individual risk factors. Generally, NSAIDs are avoided in the third trimester because of potential fetal complications. Breastfeeding mothers should consult their physician, as naproxen can be excreted in breast milk in small amounts.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Naproxen has a longer half‑life than ibuprofen, allowing less frequent dosing for chronic conditions. Compared with selective COX‑2 inhibitors, naproxen offers broader anti‑inflammatory coverage but may carry a higher gastrointestinal risk. Choice of NSAID should be individualized based on efficacy, safety profile, and patient comorbidities.

Store Naproxeno Labesfal at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture, heat and direct sunlight, and ensure the packaging remains sealed until use to maintain stability.

Naproxeno Labesfal is taken orally, usually with a full glass of water. It can be taken with or without food, although taking it with meals may reduce gastrointestinal discomfort. Patients should swallow tablets whole and not crush or chew them unless directed by a healthcare professional.

The most serious risks include gastrointestinal bleeding or ulceration, cardiovascular events such as heart attack or stroke, severe skin reactions like Stevens‑Johnson syndrome, and renal or hepatic impairment. Patients experiencing signs of these conditions should seek immediate medical attention.

Individuals with a known hypersensitivity to naproxen or other NSAIDs, those with active gastrointestinal ulcers, severe heart failure, uncontrolled hypertension, or significant renal or hepatic disease should avoid using Naproxeno Labesfal. Pregnant women in the third trimester and patients on certain anticoagulants should also consult a physician before use.